SEC Form 4 · accession 0001325812-16-000091
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Officer — CEO · Director
Period of report
Jul 19, 2016
Accepted (ET)
Jul 21, 2016 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2016 | M | 15,076 | $22.75 | A | 148,465 | D | |
| Common StockF2 | Jul 19, 2016 | S | 13,571 | $63.727 | D | 134,894 | D | |
| Common StockF3 | Jul 19, 2016 | S | 1,505 | $64.5576 | D | 133,389 | D | |
| Common Stock | Jul 20, 2016 | M | 15,075 | $22.75 | A | 148,464 | D | |
| Common StockF4 | Jul 20, 2016 | S | 600 | $64.2917 | D | 147,864 | D | |
| Common StockF5 | Jul 20, 2016 | S | 12,057 | $65.5578 | D | 135,807 | D | |
| Common StockF6 | Jul 20, 2016 | S | 2,418 | $65.9993 | D | 133,389 | D | |
| Common StockF7 | holding | — | — | — | 2,801 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $22.75 | Jul 19, 2016 | M | 15,076 | D | — | Dec 14, 2016 | Common Stock | 15,076 | 45,226 | D |
| Stock Option (right to buy)F8 | $22.75 | Jul 20, 2016 | M | 15,075 | D | — | Dec 14, 2016 | Common Stock | 15,075 | 30,151 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2015. The 30,151 options exercised and sold by the reporting person were due to expire on December 14, 2016.
- F2Sale prices ranged from $63.28 to $64.27.
- F3Sale prices ranged from $64.29 to $65.04.
- F4Sale prices ranged from $63.82 to $64.76.
- F5Sale prices ranged from $64.89 to $65.87.
- F6Sale prices ranged from $65.89 to $66.20.
- F7The reporting person owns 2,801 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F8The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.